Ribo Licenses 6 siRNA Candidates to Madrigal for up to USD 4.4b

China-based Ribo Life Science and its subsidiary Ribocure Pharmaceuticals have entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals to jointly develop six siRNA therapies for metabolic dysfunction-associated steatohepatitis (MASH). The partnership will utilise Ribo's proprietary liver-targeting RiboGalSTAR delivery platform. Ribo will grant Madrigal exclusive global rights to develop, manufacture and commercialise the clinical-stage assets, which include both single-target and dual-target siRNA candidates.

Under the agreement, Ribo will receive an upfront payment of USD 60 million and is eligible for up to a cumulative total of USD 4.4 billion, including the upfront and future development, regulatory and commercial milestone payments. Ribo will also receive royalties on global net sales of the partnered products. The deal addresses a significant unmet medical need in MASH, a progressive liver disease that can lead to fibrosis, cirrhosis and liver cancer, and represents a major global market opportunity.

PharmCube's NextBiopharm® database shows that this is the largest MASH siRNA licensing transaction so far, and the third largest in the siRNA space. Click here to request a free trial for NextBiopharm®.

Daily News
Kyverna Files First Autoimmune CAR-T Therapy with US Regulators
2026-11-16
Novo Nordisk's First Bispecific Mim8 Approved in EU for Haemophilia A
2026-11-16
Phrontline Closes USD 40 Million Series A for Bispecific and Dual-Payload ADCs
2026-11-16
Abbisko's Pimicotinib Wins FDA Approval, Extending Global TGCT Franchise
2026-11-13
Eli Radiopharma Raises RMB 400mn Series A for Radiopharma Pipeline
2026-11-13
Latest Report
AI- in-BD- Portfolio
Details